Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

PURPOSE: Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. METHODS: Postmenopausal women with HR+ , HER2− advanced breast cancer and no prior systemic therapy for advanced disease were enrolled in the Phase III MONALEESA-2 tria...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Breast Cancer Res Treat
Κύριοι συγγραφείς: O’Shaughnessy, Joyce, Petrakova, Katarina, Sonke, Gabe S., Conte, Pierfranco, Arteaga, Carlos L., Cameron, David A., Hart, Lowell L., Villanueva, Cristian, Jakobsen, Erik, Beck, Joseph T., Lindquist, Deborah, Souami, Farida, Mondal, Shoubhik, Germa, Caroline, Hortobagyi, Gabriel N.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: Springer US 2017
Θέματα:
Clinical Trial
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5847028/
https://ncbi.nlm.nih.gov/pubmed/29164421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10549-017-4518-8
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια